InSightec Fund

Private Equity

Register Interest


The law normally requires people who offer financial products to give information to investors before they invest. This information is designed to help investors make an informed decision.

If you are an accredited investor under the definition of that term in Rule 501(a) of Regulation D of the US Securities Act of 1933, the usual rules do not apply to offers of financial products made to you. As a result, you may not receive a complete and balanced set of information.

You will also have fewer other legal protections for these investments. Ask questions, read all documents carefully, and seek independent financial advice before committing yourself.

Transaction Size
USD 10,000,000.00
Share Price
USD 1.00
Minimum Investment
USD 100,000.00
Issue Type
Private Equity
Health Care

An opportunity has arisen for accredited investors as defined in Rule 501(a) of Regulation D of the US Securities Act of 1933, to register interest in an investment through a Fund into InSightec Ltd., (the “Issuer”) a private company operating in Israel and the USA. www.insightec.com. 

INSIGHTEC is a global medical technology innovator with a vision to transform healthcare by making incisionless MR-guided focused ultrasound (MRgFUS) a standard of care for patients. Focused ultrasound technology uses sound waves that pass safely through skin, bone, and muscle. The spot where the sound waves converge is heated to temperatures that cause thermal ablation. When paired with MR imaging, a complete anatomical survey of the treatment area allows for patient-specific planning and real-time monitoring.

The company's award-winning Exablate NeuroTM device is FDA-approved to treat medication-refractory essential tremor and tremor-dominant Parkinson's disease. Research for future applications in the neuroscience space is underway in partnership with leading academic and medical institutions. INSIGHTEC is headquartered in Haifa, Israel, and Miami, Florida, with offices in Dallas, Tokyo and Shanghai.

The Fund is currently in negotiations to purchase up to $10,000,000 of units in investment vehicles holding shares of the Issuer’s Preferred Stock and is exploring additional opportunities to purchase shares and/or interests in investment vehicles holding or acquiring shares. The Fund is also monitoring InSightec’s plans to issue up to an additional $50,000,000 of its Series F Preferred Stock.

Such issuance has been authorised by InSightec but it has not revealed any plans it might have to issue and sell such additional shares.

You can also see a number of media articles relating to InSightec by clicking the Documents tab.

To receive further information and be connected to the advisor, Register Interest.

Insightec wants to usher in a new era of incisionless surgery - MedCity News
April 13, 2020
A cutting-edge brain surgery for tremor, without the cutting - The Boston Globe
April 13, 2020
"Now we can do incisionless surgery" - Invterview with INSIGHTEC CEO - Thrive Global
April 14, 2020

Join our Issuer newsletter

Our quarterly Issuer newsletter is for partners, businesses and anyone interested in what we’re up to, platform updates and market commentary. To sign up to the Investor newsletter for marketplace offers click here.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.